All In Biotech

Drug Trial Radar · NCT05592626

A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors

A Phase 1/2, First-in-Human, Open-Label, Dose Escalation and Expansion Study of STAR0602, a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule, in Subjects With Unresectable, Locally Advanced, or Metastatic Solid Tumors That Are Antigen-rich (START-001)

Last checked: Nov 19, 2026Latest source record: Aug 11, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

366

Planned (sponsor's estimate)

Start

Jan 4, 2023

Primary completion

Sep 2027

Study completion Sep 2027

Sponsor

Lead sponsor
Marengo Therapeutics, Inc.Industry
Sponsor type
Industry
First posted
Oct 24, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is an open label, multicenter, phase 1/2 study to assess the safety/tolerability and preliminary clinical activity of STAR0602 as a single agent and in combination with chemotherapy administered intravenously in participants with advanced solid tumors that are antigen-rich.

Conditions

  • Advanced Solid Tumors
  • Genital Neoplasm, Female
  • Urogenital Neoplasms
  • Lung Neoplasm
  • Neoplasms by Site
  • Papillomavirus Infection
  • Epstein-Barr Virus Infections
  • Carcinoma
  • Neoplasms
  • Vulvar Neoplasms
  • Vulvar Diseases
  • Abdominal Neoplasm
  • NSCLC (Non-small Cell Lung Cancer)
  • Colorectal Cancer

Interventions

  • STAR0602Drug

    solution, intravenous infusion

  • Irinotecan (Camptosar)Combination product

    solution, intravenous infusion

  • Docetaxel (Taxotere)Combination product

    solution, intravenous infusion

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Phase 1 (Dose Escalation):Number of Participants with Dose-limiting Toxicities (DLTs) in Cycle 1Time frame: Cycle 1 (Cycle length= 28 days)
  2. Phase 1 and 2 (Dose Escalation and Expansion): Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs)Time frame: Up to 3 years
  3. Phase 2 (Dose Expansion): Percentage of Participants with Overall Objective Tumor Responses (ORR)Time frame: Up to 3 years

Locations

19 sites in 4 countries. Site status is shown where the registry gives one.

  • UC Davis Comprehensive Cancer Center

    Sacramento, California · Active not recruiting

  • AdventHealth Celebration

    Celebration, Florida · Recruiting

  • University of Miami Sylvester Comprehensive Cancer Center

    Miami, Florida · Active not recruiting

  • The University of Kansas Cancer Center

    Kansas City, Kansas · Recruiting

  • National Institutes of Health

    Bethesda, Maryland · Recruiting

  • Massachusetts General Hospital Cancer Center

    Boston, Massachusetts · Recruiting

  • Karmanos Cancer Institute

    Detroit, Michigan · Recruiting

  • The Ohio State University Comprehensive Cancer Center

    Columbus, Ohio · Recruiting

  • Sarah Cannon Research Institute Oncology Partners (SCRI-Nashville)

    Nashville, Tennessee · Recruiting

  • The University of Texas, MD Anderson Cancer Center

    Houston, Texas · Recruiting

  • UT Health Mays Cancer Center

    San Antonio, Texas · Recruiting

  • Fred Hutchinson Cancer Center

    Seattle, Washington · Active not recruiting

  • University of Wisconsin- Madison

    Madison, Wisconsin · Recruiting

  • Princess Margaret Cancer Centre

    Toronto, Ontario, Canada · Recruiting

  • Institute Gustave Roussy

    Villejuif, France · Recruiting

  • START Madrid FJD

    Madrid, Spain · Recruiting

  • Instituto de Investigacion Sanitaria, INCLIVA

    Valencia, Spain · Recruiting

  • Vall d'Hebron Institute of Oncology

    Barcelona, Catalonia, Spain · Recruiting

  • Hospital Universitario Quirónsalud Madrid

    Madrid, Spain, Spain · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.